Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.
Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.
/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Despite Bio-Techne's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's prospects.
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
The company has gained a lot of attention since launching an AI-enabled personal health app last month.